paclitaxel has been researched along with Neoplasms, Otorhinolaryngologic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, P; Algazy, K; Alonso-Basanta, M; Bauman, J; Chalian, AA; Cohen, RB; Desai, A; Grover, S; Kevin Teo, BK; Lin, A; Lukens, JN; Masroor, F; Mitra, N; O'Malley, BW; Sharma, S; Wan, F; Weinstein, GS | 1 |
| Baik, CS; Baker, KK; Chow, LQM; Eaton, KD; Goulart, B; Lee, SM; Martins, R; Pellini Ferreira, B; Redman, M; Rodriguez, CP; Santana-Davila, R | 1 |
| Blanch, JL; Caballero, M; Grau, JJ; Monzó, M; Verger, E | 1 |
| Chazard, M; Garet, F; Lavail, Y; Lenaz, L; Lucidi, B; Pellae-Cosset, B; Soares, JA | 1 |
1 review(s) available for paclitaxel and Neoplasms, Otorhinolaryngologic
| Article | Year |
|---|---|
[Taxol (paclitaxel), first molecule of a new class of cytotoxic agents: taxanes].
Topics: Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Otorhinolaryngologic Neoplasms; Ovarian Neoplasms; Paclitaxel; Spindle Apparatus | 1994 |
3 other study(ies) available for paclitaxel and Neoplasms, Otorhinolaryngologic
| Article | Year |
|---|---|
A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Disease-Free Survival; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Otorhinolaryngologic Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Tumor Burden | 2016 |
Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Otorhinolaryngologic Neoplasms; Paclitaxel; Prognosis; Treatment Outcome | 2017 |
Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Otorhinolaryngologic Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Survival Analysis | 2009 |